A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs SY 1365 (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Syros Pharmaceuticals
  • Most Recent Events

    • 11 Sep 2017 According to a Syros Pharmaceuticals media release, trial design has been presented at the European Society of Medical Oncology (ESMO) 2017 Congress.
    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 31 Aug 2017 According to a Syros Pharmaceuticals media release, design of this trial will be presented at the European Society of Medical Oncology (ESMO) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top